Lanean...
Ipilimumab in prostate cancer
INTRODUCTION: Immune checkpoint inhibitors, such as ipilimumab, are a new class of immunotherapeutic agents that have shown significant efficacy in melanoma. A number of ongoing clinical trials are investigating the role of ipilimumab in prostate cancer, either alone or in combination with immunomod...
Gorde:
| Argitaratua izan da: | Expert Opin Biol Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2012
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628899/ https://ncbi.nlm.nih.gov/pubmed/23265575 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/14712598.2012.754421 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|